-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Figure 1: The declaration of osteolytic triol softgels for pharmaceutical industry in Sichuan Source: CDE official website Figure 2: Sales of osteolytic triol Source: Minnet China's public medical institutions terminal competition pattern Minenet data show that in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal vitamin TOP20 varieties, osteolytic triol sales in the first half of 2020 growth rate of 7.8%.
Figure 3:2020H1 osteolytic triol enterprise competition pattern Source: Minet China's public medical institutions terminal competition pattern market domestic osteotisanol only Zhengda Pharmaceutical (Qingdao) was approved, the product is softgels, the enterprise also submitted a consistent evaluation of supplementary applications in July this year, is currently in review and approval.
From the market pattern, domestic brands have occupied half of the mountain, imported brands only Roche (glue pills) can compete with it, but Roche's market share has gradually declined, in the first half of 2020 only 44.5%.
, only AbbVie has received import approval, and there are currently no domestic generics.
At present, osteosterol imitation listing applications, concentrated in softgels and ointments, Sichuan Guo for pharmaceutical, Henan Taifeng biotechnology declared the softgel 4 types of imitation listing, is currently in review and approval;
source: CDE official website, Mienet database